2004 Drug Development Pharmaceuticals 
Drug Target Review
JULY 4, 2023
For instance, we can compare the data from the 2021 DESTINY gastric cancer trial using the ADC Trastuzumab Deruxtecan with data from a gastric cancer trial in 2004 using the small molecule Irinotecan. Antibody drug conjugated with cytotoxic payload. The therapeutic window of antibody drug conjugates: A dogma in need of revision.
Drug Target Review
JUNE 19, 2024
Also, many companies never reached the point where they received validation from big pharmaceutical companies. From 2002 until 2004, Mr Culley was Director of Business Development and Marketing for Immusol, Inc. Mr Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 15, 2020
She continued her career as a health economist and in 2004, Seredina joined S-Clinica. She began her career at S-Clinical as a business developer and progressed to be the Head of Operations. He has worked for a number of partner research organizations in clinical development, including Biotrial, Celerion and Parexel.
Sygnature Discovery
NOVEMBER 13, 2023
Martin LeBlanc is a seasoned pharmaceutical executive with a successful track record in driving innovation and growth within the life sciences sector. Since 2004, Sygnature Discovery has delivered over 40 novel pre-clinical and 22 clinical compounds, with its scientists named on over 170 patents.
The Pharma Data
NOVEMBER 15, 2020
Her healthcare experience spans diagnostics, medical devices, pharmaceuticals, and digital health. a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004.
New Drug Approvals
JANUARY 9, 2024
1004-1014, 2004). Inhibitors of CDK7 are currently being developed for the treatment of cancer. For drug development, it is typically advantageous to employ individual stereoisomers as they exhibit marked differences in pharmacodynamic, pharmacokinetic, and toxicological properties. Genes Dev.Oct 15;25(20):2158-72, 2011).
Drug Target Review
JUNE 21, 2023
2,3 This is exemplified by drugs that target disease-specific genes or genetically distinct patient subsets which are more likely to succeed in demonstrating efficacy in clinical development. Leveraging genetic evidence to develop new therapeutics has been successful in the past. 2004 Feb 6;303(5659):808-13.
Expert insights. Personalized for you.
145 
Let's personalize your content